Literature DB >> 30064057

Atherosclerosis in cholesterol-fed rabbits and in homozygous and heterozygous LDL receptor-deficient humans.

Gilbert R Thompson1.   

Abstract

A phenocopy is an environmentally-defined phenotype that mimics another, genetically-determined phenotype. The severity of hypercholesterolaemia, extent of down regulation of LDL receptor expression and aortic root localisation of atherosclerosis in cholesterol-fed rabbits strikingly resemble the cardinal features of homozygous familial hypercholesterolaemia (FH) in humans, suggesting that the former is a phenocopy of the latter. This review compares the metabolic and pathological consequences of induced hypercholesterolaemia in rabbits with those of homozygous FH and contrasts their ease of reversibility on resumption of a normal diet with the refractoriness to lipid-lowering therapy of homozygotes, in whom major adverse cardiovascular events and survival depend upon the prevailing level of serum cholesterol. The monofactorial nature of the atherosclerosis in both situations corroborates Anitschkow's concept that "Cholesterin ist alles." In contrast, atherosclerosis in heterozygous FH differs in several respects from that of homozygotes, notably the lack of aortic root involvement and in its multifactorial aetiology, with raised LDL cholesterol, male gender, low HDL cholesterol and raised lipoprotein (a) all contributing to its clinical expression. In angiographic trials of LDL-lowering therapy regression of coronary lesions was observed in FH heterozygotes whereas they progressed in non-FH subjects. Similarly, carotid artery plaques progressed less in FH heterozygotes than in non-FH subjects, in both instances despite FH patients having higher LDL cholesterol levels on treatment. These findings suggest that, compared with non-FH subjects, atherosclerotic lesions in FH heterozygotes may be hyper-responsive to LDL-lowering therapy, whereas treatment of homozygous FH remains a major challenge.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Aortic root; Heterozygous familial hypercholesterolaemia; Homozygous familial hypercholesterolaemia; Lipid-lowering therapy

Mesh:

Substances:

Year:  2018        PMID: 30064057     DOI: 10.1016/j.atherosclerosis.2018.07.032

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  2 in total

1.  Efficacy and Safety of PCSK9 Monoclonal Antibodies in Patients at High Cardiovascular Risk: An Updated Systematic Review and Meta-Analysis of 32 Randomized Controlled Trials.

Authors:  Guangyan Mu; Qian Xiang; Shuang Zhou; Zhiyan Liu; Litong Qi; Jie Jiang; Yanjun Gong; Qiufen Xie; Zining Wang; Hanxu Zhang; Yong Huo; Yimin Cui
Journal:  Adv Ther       Date:  2020-02-27       Impact factor: 3.845

Review 2.  Current Role of Lipoprotein Apheresis.

Authors:  Gilbert Thompson; Klaus G Parhofer
Journal:  Curr Atheroscler Rep       Date:  2019-05-01       Impact factor: 5.113

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.